Davy forecasts 18% revenues leap for Tysabri

Stockbroker Davy has said US Q4 revenues for Elan drug Tysabri could be 18% ahead of forecasts.

Using latest IMS Health sales data for October and November, Davy has estimated that Q4 Tysabri revenues could come in around $97m (€66m), which would be 18% ahead of our forecasts of $82m (€56m).

IMS data suggest that the multiple sclerosis (MS) market in the US is growing at about 10% year-on-year, due mainly to price increases. Latest data indicate that Tysabri is capturing at least 33% of this growth.